Fibrinolytic activity disturbances in malignant blood diseases. 1988

K Hrubisková, and M Hrubisko
Department of Haematology and Transfusiology, Postgraduate Medical School, Bratislava, CSSR.

Repeated investigation of 105 patients suffering from different blood disorders demonstrated a more frequent occurrence of disturbances in fibrinolysis (66% as in blood clotting tests (40%) indicating a compensated or decompensated intravascular blood clotting. In the group of patients with thrombocythaemia the disturbance of fibrinolysis as much as in 83% was present, and always in sense of insufficiency. In myeloproliferative diseases without proliferation of megakaryocytes the antithrombotic treatment improved both the fibrinolysis as well as the clotting disturbances. In thrombocythaemia the long-termed treatment with anti-platelet drugs, eventually with other antithrombotics favourably influenced the blood clotting parameters as well as the symptomatology from vascular occlusion, however the euglobulin lysis remained unchanged. In sense of the idea on the ineffective megakaryocytopoiesis in primary and other myeloproliferative diseases accompanying thrombocythaemia attention is called to the specificity of the fibrinolytic insufficiency in thrombocythaemia in comparison with other myeloproliferative diseases without thrombocythaemia.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias

Related Publications

K Hrubisková, and M Hrubisko
April 1971, The Journal of the Association of Physicians of India,
K Hrubisková, and M Hrubisko
January 1970, Angiologica,
K Hrubisková, and M Hrubisko
September 1974, Polski tygodnik lekarski (Warsaw, Poland : 1960),
K Hrubisková, and M Hrubisko
November 1975, Journal of clinical pathology,
K Hrubisková, and M Hrubisko
November 1969, Indian journal of medical sciences,
K Hrubisková, and M Hrubisko
January 1964, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde,
K Hrubisková, and M Hrubisko
December 1991, Indian journal of cancer,
K Hrubisková, and M Hrubisko
March 1961, Polski tygodnik lekarski (Warsaw, Poland : 1960),
K Hrubisková, and M Hrubisko
September 1956, Klinische Wochenschrift,
K Hrubisková, and M Hrubisko
April 1966, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
Copied contents to your clipboard!